Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 4.7M | 264.6% |
| Gross Profit | -3.1M | 13.7% |
| Cost of Revenue | 7.8M | 94.6% |
| Operating expense | 23M | 1.7% |
| Net Income | -14M | 27.5% |
| EBITDA | -19M | 1.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 110M | 12.2% |
| Total Liabilities | 38M | 2.7% |
| Total Equity | 72M | 16.6% |
| Shares Outstanding | 13M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -18M | 21.8% |
| Cash from investing | -31,000 | 31.1% |
EPS
Financial Highlights for Hookipa Pharma in Q3 '24
Hookipa Pharma reported a revenue of 4.7M, which is a 264.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -3.1M, marking a -13.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 7.8M, a 94.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 23M, showing a -1.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -14M, showing a 27.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -19M, showing a -1.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Hookipa Pharma faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
